Centre for Health Economics and Medicines Evaluation, Ardudwy, Normal Site, Bangor University, Bangor, Gwynedd, Wales, UK.
Clin Pharmacol Ther. 2018 May;103(5):749-751. doi: 10.1002/cpt.1030. Epub 2018 Feb 13.
Economic evaluations have dispelled a perception that precision medicine, achieved through pharmacogenetic testing, reduces healthcare costs. For many tests aimed at preventing adverse drug reactions, cost-effectiveness analyses predict modest improvements in health benefits and increases in total costs. While there are many uncertainties in estimating the value of testing, factors that influence cost-effectiveness include the rarity of the outcome, the effectiveness of alternative treatments, and the scope and perspective of analysis.
经济评估消除了一种看法，即通过药物遗传学检测实现的精准医疗会降低医疗成本。对于许多旨在预防药物不良反应的检测，成本效益分析预测健康效益会有适度改善，总费用会增加。虽然在估计检测价值时存在许多不确定性，但影响成本效益的因素包括结果的罕见性、替代治疗的有效性，以及分析的范围和角度。
